UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2015
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware |
|
001-36457 |
|
90-0031917 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866) 594-5999
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
(a) Provectus Biopharmaceuticals, Inc. (the
Company) held its annual meeting of stockholders on Friday, June 19, 2015.
(b) At the annual meeting, the Companys stockholders
voted on three proposals. A brief description of and tabulation of votes for each proposal are set forth below.
Proposal 1. The
Companys stockholders elected the following directors for a term of one year. There were 70,596,501 broker non-votes with respect to the proposal.
|
|
|
|
|
|
|
|
|
Nominee |
|
For |
|
|
Withheld |
|
H. Craig Dees, Ph.D. |
|
|
56,215,984 |
|
|
|
3,733,078 |
|
Timothy C. Scott, Ph.D. |
|
|
51,718,577 |
|
|
|
8,230,485 |
|
Jan E. Koe |
|
|
52,796,995 |
|
|
|
7,152,067 |
|
Kelly M. McMasters, M.D., Ph.D. |
|
|
57,268,275 |
|
|
|
2,680,787 |
|
Alfred E. Smith, IV |
|
|
57,376,314 |
|
|
|
2,572,748 |
|
Proposal 2. The Companys stockholders approved the advisory vote on the compensation of the
Companys named executive officers. There were 70,596,501 broker non-votes with respect to the proposal.
|
|
|
|
|
For |
|
Against |
|
Abstain |
40,296,537 |
|
11,655,544 |
|
7,996,981 |
Proposal 3. The Companys stockholders ratified the selection of BDO USA, LLP as the
Companys independent auditor for 2015. There were no broker non-votes with respect to the proposal.
|
|
|
|
|
For |
|
Against |
|
Abstain |
126,720,215 |
|
1,152,287 |
|
2,673,061 |
Item 7.01. |
Regulation FD Disclosure. |
On June 22, 2015, Provectus Biopharmaceuticals, Inc.
issued a press release (the Press Release) announcing that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma
Conference from August 13-15, 2015 in Goiania, Brazil. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the information
in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be filed under the Securities Exchange Act of 1934.
Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release, dated June 22, 2015 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: June 22, 2015
|
|
|
PROVECTUS BIOPHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Peter R. Culpepper |
|
|
Peter R. Culpepper |
|
|
Chief Financial Officer and Chief Operating Officer |
3
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release, dated June 22, 2015 |
Exhibit 99.1
|
|
|
Contact: |
|
|
Provectus Biopharmaceuticals, Inc. |
|
Porter, LeVay & Rose, Inc. |
Peter R. Culpepper, CFO, COO |
|
Marlon Nurse, DM, SVP Investor Relations |
Phone: 866-594-5999 #30 |
|
Phone: 212-564-4700 |
|
|
Todd Aydelotte Media Relations |
|
|
Phone: 646-428-0644 |
FOR IMMEDIATE
RELEASE
PROVECTUS BIOPHARMACEUTICALS RETAINS PHARMAHEALTHLABS TO FACILITATE INVESTIGATOR ADVISORY BOARD MEETING DURING 11TH BRAZILIAN MELANOMA CONFERENCE
Briefing for Approximately 15 Brazilian Melanoma
Specialists in Goiania, Brazil
KNOXVILLE, TN, June 22, 2015 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a
clinical-stage oncology and dermatology biopharmaceutical company (Provectus or the Company), announced that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator
Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil.
The meeting will target approximately 15 key oncologists who will be attending the conference and who are active in the investigator community in Brazil for
the treatment of melanoma. The purpose is to offer insight and feedback into the status of treatment of melanoma in Brazil as well as the feasibility of initiating the PV-10 Trial in Brazil.
Under the terms of the agreement, PharmaHEALTHLabs will provide a dedicated management team to handle numerous functions at which their company excels. This
includes, but is not limited to, content development; overall account and project management; participant recruitment, planning and contracting; expense accounting functions; development of meeting materials; venue research and contracting; program
coordination and logistics; travel and accommodations; onsite support; and meeting summary and reporting.
Peter Culpepper, CFO and COO, of Provectus
said, The 11th Brazilian Melanoma Conference is a gathering of melanoma experts from all around Brazil, a country where melanoma survival rates are lower than average, that offers us a
unique opportunity to explore the possibilities of extending our melanoma research into Brazil. PharmaHealthLabs personnel are highly experienced in melanoma and in managing the kind of meeting we need to have with the leading investigators in
the country, and we are confident that their efforts will help us quickly and clearly understand the potential of Brazil in our PV-10 development program.
Jeff Meehan, PharmaHealthLabs Lead Oncology Advisor, said, PharmaHealthLabs is very happy to be working with Provectus in assessing the potential of
Brazil as a place for further research into PV-10 in melanoma. Putting together this kind of high level meeting on an international level requires agility as well as experience, and we believe that Provectus will be highly pleased with the quality
of the information they receive.
About PharmaHEALTHLabs
PharmaHEALTHLabs is a healthcare communications company based in Morristown, NJ that creates compelling solutions for life sciences companies.
PharmaHEALTHLabs combines insightful strategy, award-winning creative, and high impact editorial with practical know-how, ensuring each project is not only
compelling and engaging, but also simple to understand and communicate. We are nimble, agile, and cutting edge. We treat every customer and every project with respect and personalization. We provide teams dedicated to a clients business so
there is a consistent point of contact that can continue to build on learnings over time. We strive to give our clients the best experience possible when dealing with a solutions agency.
About Provectus Biopharmaceuticals, Inc.
Provectus
Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Companys other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit
the Companys website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
forward-looking statements as defined under U.S. federal securities laws. These statements reflect managements current knowledge, assumptions, beliefs, estimates, and expectations and express managements current views of
future performance, results, and trends and may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may,
plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those
described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed
in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:
|
|
|
our determination, based on guidance from the FDA, whether to proceed with or without a partner with the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with
such a trial if it is necessary to complete (versus interim data alone); |
|
|
|
our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver; |
|
|
|
our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies; and |
|
|
|
our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to
commercialization. |
###
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024